{
    "clinical_study": {
        "@rank": "84125", 
        "arm_group": {
            "arm_group_label": "Ezetimibe, dyslipidemia, kidney transplant", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "In kidney transplant patients atherosclerosis process is accelerated even in asymptomatic\n      patients. This is mainly the consequence of immunosuppressive therapy. Dyslipidemia is\n      treated with statins in low doses only as high doses can lead to rhabdomyolysis and are\n      therefore contraindicated. As second lipid lowering agent most commonly ezetimibe is used.\n      The investigators hypothesise that ezetimibe as a second lipid lowering drug in kidney\n      transplant patients lowers LDL cholesterol for additional 10 per cent."
        }, 
        "brief_title": "The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Dyslipidemia", 
            "Transplants"
        ], 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "detailed_description": {
            "textblock": "In addition to observing the lipid profile the investigators intend to look for other\n      pathophysiological effects of ezetimibe, such as its influence on oxidative stress,\n      endothelial function and inflammatory biochemical markers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        LDL > 2.5 mM, Already treated with statin, Stable renal function of various GFR, Men or\n        women older than 18 years, Signed informed consent.\n\n        Exclusion Criteria:\n\n        Acute heart disease or any heart disease in the last 3 months, kidney graft failure,\n        active systemic inflammatory disease, active malignant disease, chronic diarrhea and\n        malabsorption, transaminases increased > 3 fold, creatin kinase increased > 5 fold,\n        hypersensitivity reactions, active peptic ulcer disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103049", 
            "org_study_id": "UMCL-2014-TX"
        }, 
        "intervention": {
            "arm_group_label": "Ezetimibe, dyslipidemia, kidney transplant", 
            "description": "Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.", 
            "intervention_name": "Ezetimibe", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ezetimibe"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "email": "gregor.mlinsek@gmail.com", 
                "last_name": "Gregor Mlinsek", 
                "phone": "+ 386 1 522 2978"
            }, 
            "facility": {
                "address": {
                    "city": "Ljubljana", 
                    "country": "Slovenia", 
                    "zip": "1000"
                }, 
                "name": "University Medical Center Ljubljana"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Slovenia"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients", 
        "overall_contact": {
            "email": "gregor.mlinsek@gmail.com", 
            "last_name": "Gregor Mlinsek, MD, PhD"
        }, 
        "overall_official": {
            "affiliation": "University Medical Center Ljubljana, Slovenia", 
            "last_name": "Gregor Mlinsek, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Slovenia: Agency for Medicinal Products - Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The investigators expect the LDL cholesterol concentration to lower for at least 10%.", 
            "measure": "Decrease of LDL cholesterol concentration.", 
            "safety_issue": "No", 
            "time_frame": "At enrolment, at three, six and nine months thereafter."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103049"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Medical Centre Ljubljana", 
            "investigator_full_name": "Gregor Mlinsek", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change in oxidative markers, inflammation and endothelial function.", 
            "measure": "Change in oxidative markers", 
            "safety_issue": "No", 
            "time_frame": "At enrolment, at three, six and nine months thereafter."
        }, 
        "source": "University Medical Centre Ljubljana", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Medical Centre Ljubljana", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}